Prostamax
OtherPreclinicalAlso known as: Prostate peptide
Prostamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "prostate bioregulator" intended to support prostatic epithelium and stromal function in age-related benign prostatic hyperplasia (BPH), chronic prostatitis, and post-surgical prostate recovery.
Overview
At A Glance
Mechanism of Action…
Mechanism of Action
Mechanism of Action
Prostamax's proposed mechanism is the Khavinson short-peptide framework applied to prostate tissue: passive membrane permeation, nuclear import, and sequence-selective chromatin modulation producing prostate-favourable transcriptional shifts.
Step 1 — Tissue distribution. At ~473 daltons (H-Lys-Glu-Asp-Pro-OH), Prostamax is small and sufficiently polar to cross phospholipid bilayers passively. Khavinson tritiated-peptide biodistribution work describes uptake across multiple tissues (Khavinson et al., 2014). The prostate is anatomically divided into peripheral, central, and transition zones with different epithelial and stromal characteristics. Whether Prostamax reaches each zone's cells at functionally meaningful concentrations has not been established.
Step 2 — Prostate cell targeting. The framework-level claim is zone-selective or cell-type-selective prostate uptake. No direct experimental validation exists. Prostate tissue has a specific blood-prostate barrier and drug penetration patterns (relevant for antibiotic selection in prostatitis); whether KEDP penetrates this barrier efficiently is unknown.
Step 3 — Chromatin modulation of prostate programmes. Russian in vitro work describes modulation of prostatic epithelial cell proliferation, reduced apoptosis markers under stress, and changes in androgen receptor signalling markers in cultured prostate cells (Khavinson et al., 2011). The proposed mechanism is preferential activation of prostatic homeostatic transcription programmes. Modern prostate biology methodology — single-cell transcriptomics on prostate organoids, ChIP-seq in prostate epithelial cells, CRISPR-based target validation — has not been applied to Prostamax.
Alternative conservative framing
A parsimonious interpretation treats Prostamax as an amino-acid source delivering lysine, glutamate, aspartate, and proline. Biological effects could reflect: (a) substrate delivery for prostatic protein synthesis, (b) proline-mediated collagen synthesis in prostate stroma, (c) glutamate/aspartate TCA cycle anaplerosis, or (d) non-specific nutritional support. Under this framing, equivalent amino-acid delivery by any means would produce similar effects.
Comparison to evidence-graded BPH mechanisms
- Alpha-1 adrenoceptor antagonists (tamsulosin, alfuzosin, silodosin) — block smooth muscle contraction in prostatic stroma and bladder neck, producing measurable urinary flow improvement. Receptor pharmacology mapped, decades of RCT data.
- 5-alpha reductase inhibitors (finasteride, dutasteride) — block conversion of testosterone to DHT, reducing prostate size over months. Androgen pathway understood, long-term RCT data available.
- PDE5 inhibitors (tadalafil 5 mg daily) — improve LUTS via NO/cGMP pathway, particularly useful when BPH and erectile dysfunction overlap. Mechanism characterised.
- Anticholinergics and beta-3 agonists — reduce detrusor overactivity in overactive bladder component of LUTS.
- Saw palmetto — proposed 5-alpha reductase inhibition plus anti-inflammatory effects. Clinical trials heterogeneous, with some showing benefit and others (STEP trial) showing no effect above placebo.
- Pygeum africanum — anti-inflammatory and growth-modulating effects on prostate. Modest evidence base.
Prostamax sits at a different level of mechanistic specification — framework-level hypothesis rather than measured pharmacology of defined targets.
Comparison to Prostatilen/Vitaprost
The parent polypeptide extract has modestly more clinical evidence — Russian RCT-style trials in BPH, chronic prostatitis, and male infertility associated with chronic prostatitis report improvements in IPSS scores, prostate-specific inflammation markers, and ejaculate quality (Kuznetsov et al., 2014). Whether the synthetic KEDP reproduces the extract's effects has not been systematically tested. It is an open question whether the active component of the extract is KEDP, a different peptide, or a mixture of factors.
Receptor pharmacology
No GPCR, nuclear receptor, or defined enzyme target identified for Prostamax. It does not bind androgen receptor, alpha-adrenoceptors, or PDE5. It does not inhibit 5-alpha reductase. It does not directly affect inflammatory pathways (COX, LOX, NF-κB) at characterised concentrations. The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class.
Relation to other male-health compounds
Among peptides relevant to male health, Semax and Selank have better-characterised neurological mechanisms and more published literature. BPC-157 has better-characterised tissue regeneration data. Among non-peptide prostate supplements, saw palmetto, beta-sitosterol, Pygeum, and rye pollen extracts all have more clinical data than Prostamax. Among prescription prostate medications, alpha-blockers, 5-alpha reductase inhibitors, and PDE5 inhibitors sit in a fundamentally different evidence tier.
Overview
Prostamax is a short synthetic peptide developed in Russia by Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology, positioned as a "prostate bioregulator" intended to support prostatic epithelium and stromal function in age-related benign prostatic hyperplasia (BPH), chronic prostatitis, and post-surgical prostate recovery. It is usually described in Khavinson-family publications as the tetrapeptide Lys-Glu-Asp-Pro (KEDP), sometimes rendered H-Lys-Glu-Asp-Pro-OH or K-E-D-P. Prostamax is the synthetic defined-sequence counterpart to Prostatilen (sometimes marketed as Vitaprost), a polypeptide extract prepared from bovine prostate tissue that has been used clinically in Russia since the 1980s and remains a registered pharmaceutical in the Russian Federation for BPH and chronic prostatitis. Prostamax sits alongside Pinealon, Thymogen, Vilon, Epitalon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, Ovagen, and Testagen within the Khavinson short-peptide bioregulator family.
Outside Russia, Prostamax is not a registered pharmaceutical, not FDA- or EMA-reviewed, not listed in WADA categories, and does not appear in AUA, EAU, or NICE guidelines for BPH or chronic prostatitis management. The parent polypeptide extract (Prostatilen/Vitaprost) has a modestly larger evidence base than the synthetic tetrapeptide, with some Russian RCT-style trials reporting benefit in chronic pelvic pain syndrome and BPH symptom scores (Kuznetsov et al., 2014; Avdoshin et al., 2015). The synthetic Prostamax tetrapeptide evidence base is substantially smaller, comprising Khavinson-group in vitro work, small rodent experiments, and uncontrolled observational series (Khavinson et al., 2011; Anisimov et al., 2010).
The central claim for Prostamax is the standard Khavinson short-peptide model applied to prostate tissue: passive membrane permeation into prostatic epithelial and stromal cells, nuclear import, and sequence-selective chromatin modulation producing preferential upregulation of prostatic homeostatic programmes while downregulating inflammatory and hyperproliferative patterns. The tissue-specific targeting claim — that KEDP selectively supports prostate rather than other reproductive or visceral tissue — is asserted within the Khavinson framework but not validated by modern biodistribution, structural biology, or prostate-specific transcriptomics.
BodyHackGuide covers Prostamax because it is sold online in post-Soviet supplement channels (typically 20 mg oral capsules or rectal suppositories) and appears in longevity and male-health discussions as a prostate-support bioregulator. We describe what is known, what is claimed, and what is missing — and we steer readers seeking evidence-graded prostate care toward interventions with substantial replication: PSA screening appropriate for age and risk, evaluation of lower urinary tract symptoms (LUTS) with IPSS scoring and urological workup, evidence-based pharmacotherapy for BPH (alpha-blockers like tamsulosin, 5-alpha reductase inhibitors like finasteride or dutasteride, phosphodiesterase-5 inhibitors like tadalafil for LUTS/ED overlap), evidence-based chronic prostatitis management, proven supplements (saw palmetto with mixed but some evidence, Pygeum, beta-sitosterol), surgical or minimally invasive procedures where indicated (TURP, Rezum, UroLift, HoLEP), and definitive management of prostate cancer where diagnosed. Prostamax is a plausible hypothesis. It is not, in 2026, an evidence-graded prostate therapy.
Chemical Information
IUPAC Name
L-Lysyl-L-glutamyl-L-aspartyl-L-proline
CAS Number
Not yet available
Molecular Formula
Lys-Glu-Asp-Pro
Molecular Mass
472.48 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Contraindications
Absolute contraindications
- Active prostate cancer or recent history
- Elevated PSA under investigation — complete workup first
- Unexplained haematuria — evaluate before use
- Acute urinary retention — medical emergency
- Active bacterial prostatitis or UTI — antibiotic therapy required
- Paediatric and adolescent use — not applicable
- Known hypersensitivity to Prostamax or any Khavinson bioregulator
- For extract/suppository form: bovine/porcine protein allergy
Relative contraindications (supervised use only)
- Severe BPH with complications (recurrent UTI, bladder stones, hydronephrosis)
- Recent prostate surgery (within 6 weeks)
- Post-prostatectomy with PSA surveillance — coordinate with urology
- Rectal/anal disease — for suppository form
- Severe renal or hepatic impairment
- Active radiation therapy to prostate
Use with caution
- Multiple BPH medications — alpha-blocker + 5-ARI + anticholinergic polypharmacy
- TRT with ongoing PSA monitoring — maintain PSA surveillance
- Age 80+ with polypharmacy
- Coagulopathy — for suppository form (rectal bleeding risk)
Quality-of-supply contraindication
Require third-party HPLC testing. For suppository form, pharmaceutical-grade manufacturing required.
Symptoms requiring evaluation, not bioregulators
Blood in urine, dysuria with fever, acute urinary retention, rising PSA, new haematospermia, weight loss with urinary symptoms, bone pain — urological evaluation required, not Prostamax self-treatment.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Prostamax.
Related Compounds
View AllAminotadalafil
OtherPreclinicalAminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.
B7-33
OtherPreclinicalB7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.
KSPTN
OtherPreclinicalKSPTN is a novel research peptide available from select peptide research vendors.
Melanotan I
OtherFDA ApprovedMelanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.
PNC-27
OtherPreclinicalPNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells.
RU-58841
OtherPreclinicalRU-58841 (also known as PSK-3841 or HMR-3841, and commonly written simply as RU in hair-loss forums) is a non-steroidal androgen receptor antagonist originally developed by Roussel Uclaf (later absorbed into Sanofi) in the late 1980s and early 1990s.
View Full Dosage Guide →
Protocols, calculator & safety for Prostamax
Research Score
6 PubMed studies
Quality Indicators
Data Completeness
88%Research Credibility
Limited research available
Quick Facts
Molecular Weight
472.48 g/mol
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Prostamax and what is it claimed to do?
Prostamax is a synthetic tetrapeptide (Lys-Glu-Asp-Pro, KEDP) from Vladimir Khavinson's St. Petersburg Institute, positioned as a prostate bioregulator for benign prostatic hyperplasia (BPH), chronic prostatitis, and age-related prostate decline. It is the defined-sequence counterpart to Prostatilen (Vitaprost), a bovine prostate polypeptide extract that is a registered Russian pharmaceutical. Claims include supporting prostatic epithelium, stromal function, and modulating inflammatory and hyperproliferative patterns. Russian literature reports in vitro prostate cell effects and observational series in BPH and prostatitis patients (Khavinson et al., 2011; Kuznetsov et al., 2014). Not FDA/EMA-approved, not in AUA or EAU guidelines. Treat as experimental.
Does Prostamax actually help with BPH or prostatitis?
The parent polypeptide extract (Prostatilen/Vitaprost) has modestly more evidence than the synthetic Prostamax tetrapeptide, including some Russian RCT-style trials showing IPSS score improvement in chronic prostatitis and BPH (Kuznetsov et al., 2014; Avdoshin et al., 2015). The synthetic Prostamax evidence base is substantially smaller — primarily Khavinson-group in vitro work and uncontrolled observational series. For evidence-graded BPH management, first-line is alpha-blockers (tamsulosin, alfuzosin, silodosin), 5-alpha reductase inhibitors (finasteride, dutasteride) for larger prostates, PDE5 inhibitors (tadalafil 5 mg daily) for LUTS/ED overlap. Prostamax is a speculative adjunct, not a substitute.
What is the correct Prostamax dose?
Khavinson convention: 20 mg oral/sublingual capsule once daily for 10 consecutive days, 60–90 day washouts. 20 mg capsule contains undisclosed actual KEDP content (historically 2–4 mg). Subcutaneous synthetic peptide: 2–5 mg daily for 10 days. Rectal suppository (Prostatilen/Vitaprost extract form): 50 mg rectally 1–2 times daily for 10–14 days per manufacturer label. Do not use suppository form within 48 hours of PSA testing.
How does Prostamax compare to tamsulosin, finasteride, and prescription BPH drugs?
Prescription BPH drugs sit at a fundamentally higher evidence tier. Tamsulosin 0.4 mg produces measurable urinary flow improvement within days through mapped alpha-1A receptor blockade. Finasteride 5 mg reduces prostate size by ~25% over 6–12 months through 5-alpha reductase inhibition. Tadalafil 5 mg daily improves LUTS and ED through NO/cGMP pathway. All three are RCT-validated, FDA-approved, and in every major urological guideline. Prostamax is framework-level hypothesis about chromatin, not measured pharmacology. For any man with bothersome BPH, prescription pharmacotherapy first; Prostamax as tier-10+ experimental adjunct.
Is Prostamax safe?
Short-term safety signal from Russian literature is mild — occasional nausea, headache, rare rash. Suppository form may cause mild local irritation. No serious urological adverse events reported at convention dosing. However, long-term pharmacovigilance is absent. Absolute contraindications include active prostate cancer, elevated PSA under investigation, unexplained haematuria, acute urinary retention, active bacterial prostatitis, and bovine/porcine protein allergy (for extract form). Use only with third-party HPLC-verified product. Maintain standard PSA surveillance if appropriate for age and risk.
Can I use Prostamax with my existing BPH medications?
Yes, from an interaction standpoint. No documented pharmacokinetic or pharmacodynamic interactions between Prostamax and alpha-blockers (tamsulosin, alfuzosin, silodosin), 5-alpha reductase inhibitors (finasteride, dutasteride), PDE5 inhibitors (tadalafil), or antimuscarinics. Continue prescription BPH therapy through Prostamax cycles — do not substitute. Notify your urologist of any bioregulator use for complete medication documentation.
Should I use synthetic Prostamax or Prostatilen/Vitaprost extract?
Prostatilen/Vitaprost has modestly more clinical evidence, is a registered Russian pharmaceutical with standardised manufacturing, and is available as rectal suppository (direct local delivery to prostate). Synthetic Prostamax has less evidence but is chemically defined and can be oral/subcutaneous. For a user prioritising evidence within the Khavinson framework, the parent extract suppository form is the stronger choice. For a user prioritising chemical definition and avoiding bovine tissue origin, synthetic Prostamax is preferable. Both occupy the same experimental tier relative to evidence-graded BPH pharmacotherapy.
Can Prostamax prevent or treat prostate cancer?
No. Prostamax has no evidence for prostate cancer prevention or treatment and is explicitly contraindicated in active prostate cancer. The theoretical chromatin-modulating mechanism creates concern (not established benefit) in proliferative disease of the target organ. For prostate cancer prevention, evidence-based approaches are appropriate screening discussion (PSA risk-benefit with your clinician based on age, family history, race), healthy lifestyle, and potentially 5-alpha reductase inhibitors in select populations (which reduce overall prostate cancer risk but increase high-grade cancer risk — complicated risk-benefit). For prostate cancer treatment, consult oncology and urology immediately.
How does Prostamax compare to saw palmetto, Pygeum, and prostate supplements?
Saw palmetto 320 mg standardised daily has heterogeneous RCT evidence (some benefit shown, some trials including STEP showing no effect above placebo). Pygeum africanum 100–200 mg daily has modest evidence for BPH symptoms. Beta-sitosterol 60–130 mg daily has modest evidence. Rye pollen extract has modest evidence. All four sit above Prostamax in evidence weight, have more standardised products, and are dramatically cheaper. For a man interested in supplement-based BPH support, prioritise saw palmetto + Pygeum + beta-sitosterol + zinc before Prostamax.
If I have BPH symptoms and see a BodyHackGuide ad, what should I actually do?
Evidence-graded priority: (1) urologist consultation with IPSS score, PSA (age-appropriate), physical examination including DRE, urinalysis — rule out prostate cancer, infection, and other conditions; (2) lifestyle — fluid management, caffeine/alcohol moderation, bladder training, weight management; (3) alpha-blocker (tamsulosin 0.4 mg daily) for moderate-severe LUTS; (4) 5-alpha reductase inhibitor (finasteride 5 mg or dutasteride 0.5 mg daily) for larger prostates; (5) PDE5 inhibitor (tadalafil 5 mg daily) for LUTS/ED overlap; (6) saw palmetto 320 mg standardised daily; (7) Pygeum 100–200 mg daily; (8) beta-sitosterol 60–130 mg daily; (9) zinc 15–30 mg daily; (10) minimally invasive or surgical procedures for treatment-resistant disease; (11) experimental bioregulators like Prostamax or Prostatilen as tier-11 add-ons. Use ads to convert BPH-interested traffic to evidence-graded content; offer Prostamax only to users who have exhausted proven options.
Research Tools
Related Compounds
View AllAminotadalafil
OtherPreclinicalAminotadalafil is an unapproved research analog of tadalafil, the PDE5 inhibitor marketed under the brand name Cialis for erectile dysfunction and under Adcirca for pulmonary arterial hypertension.
B7-33
OtherPreclinicalB7-33 is a single-chain, 26-amino-acid peptide engineered as a functionally selective agonist of the relaxin family peptide receptor 1 (RXFP1), designed to recapitulate the therapeutic activity of human H2 relaxin — the endogenous peptide hormone that is naturally elevated during pregnancy and has broad cardioprotective, vasodilatory, and anti-fibrotic effects.
KSPTN
OtherPreclinicalKSPTN is a novel research peptide available from select peptide research vendors.
Melanotan I
OtherFDA ApprovedMelanotan I (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with the substitution of norleucine at position 4 and D-phenylalanine at position 7.
PNC-27
OtherPreclinicalPNC-27 is a p53-derived peptide that selectively induces membranolysis in cancer cells.
RU-58841
OtherPreclinicalRU-58841 (also known as PSK-3841 or HMR-3841, and commonly written simply as RU in hair-loss forums) is a non-steroidal androgen receptor antagonist originally developed by Roussel Uclaf (later absorbed into Sanofi) in the late 1980s and early 1990s.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.